Associated tags: Biotechnology, Intellectual property, TSX Venture Exchange, Biofilm, Research, KNE, Pharmaceutical industry
Locations: ITALY, WASHINGTON, NEVADA, AURORA, NOVA SCOTIA, HAWAII, WINNIPEG, MB, CA, NV, SOUTH AMERICA, MANITOBA, KANE
WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time.
Key Points:
- WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time.
- Marc Edwards, Kane's President & CEO, will share his thoughts on what the sale of STEM Animal Health, which should ultimately net Kane more than $13 million CND, means for Kane as an important step in becoming a market leader in the growing high-value wound care and dermatological markets.
- The transaction, which focuses the company and significantly improves the balance sheet, will provide the necessary capital to achieve key milestones such as commercial launches and global growth, as well as our clinical programs in both wound care and acne.
Overall, it is anticipated that the sale of STEM will net Kane an estimated CND $11,500,000.
Key Points:
- Overall, it is anticipated that the sale of STEM will net Kane an estimated CND $11,500,000.
- The Transaction was completed by way of a share purchase agreement between Kane, STEM, Ecuphar NV and Dechra dated April 12, 2024.
- In connection with the Transaction, Kane also entered into a product development agreement, and a transitional manufacturing agreement with STEM.
- In connection with the completion of the Transaction, Kane obtained the written consent of shareholders of Kane holding more than 50% of the common shares of Kane.
Overall, it is anticipated that the sale of STEM Animal Health will net Kane Biotech in excess of CND $11,500,000 (including the cash deposits already received, as noted below).
Key Points:
- Overall, it is anticipated that the sale of STEM Animal Health will net Kane Biotech in excess of CND $11,500,000 (including the cash deposits already received, as noted below).
- The Purchaser is not a Non-Arm’s Length Party (as that term is defined by the TSX Venture Exchange) of the Company.
- “We are pleased with the outcome of this transaction,” said Marc Edwards, President & CEO of Kane Biotech.
- “Kane Biotech will be receiving full value for the successful animal health business that it created allowing the Company to significantly strengthen its balance sheet and narrow its focus on human health biofilm solutions.”
Prior to the completion of the Transaction, the Company owned a 2/3 interest in STEM.
Diabetic foot,
Financial statement,
PIN,
Ulcer,
Symposium,
Sale,
KNE,
Pivot,
Credit,
Leg,
SAWC,
US FDA,
Patent,
FDA,
Government,
Food WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
Key Points:
- WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
- On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health.
- Gross profit for the fourth quarter of 2023 was $398,234, an increase of 24% compared to $320,653 for the fourth quarter ended December 31, 2022.
- Loss for the fourth quarter of 2023 was ($1,611,894), an increase of 92% compared to ($838,150) for the quarter ended December 31, 2022.
Retrieved on:
Wednesday, March 20, 2024
WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.
Key Points:
- WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.
- Kane further announces that subsequent to the US $625,000 deposit that it received at the time of the offer, Kane has received additional deposits totaling US $900,000 which will be applied towards the sale price of Kane’s interest in STEM.
Kane Biotech management will host a conference call at 4:30 p.m.
Key Points:
- Kane Biotech management will host a conference call at 4:30 p.m.
- ET to review the financial results and discuss business developments in the period.
- It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
- A webcast of the call will be available on the Company's website at www.kanebiotech.com in the Investor section of the Kane Biotech website at ir.kanebiotech.com .
WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.
Key Points:
- WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.
- Marc Edwards, President & CEO, accepted the award on behalf of the Company.
- “We’re very honoured to be the recipient of this prestigious award.
- The following link includes a video about Kane Biotech that was produced by BAM and presented at the Awards dinner: https://kanebiotech.com/#videos
Retrieved on:
Thursday, February 22, 2024
Theta,
Doctor of Philosophy,
Catheter,
FDA,
University,
Food,
Sigma Theta Tau,
Skin care,
Leadership studies,
Nephrology,
Executive,
KNE,
Management WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company.
Key Points:
- WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company.
- Mr. Huizinga has also been appointed by the directors of the Company as Executive Chair of the Company.
- Dr. Huizinga has been a member of Kane Biotech’s Scientific Advisory Board since 2018.
- “I’m excited that the Board accepted my recommendation to add Robert to the Board and to appoint him to the Executive Chair role,” said Marc Edwards, President & Chief Executive Officer.
Retrieved on:
Wednesday, January 31, 2024
Burn,
Pain,
FDA,
Skin,
Water,
Risk,
Infection,
Wound healing,
Patent,
Burns,
KNE,
Cosmetics WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.
Key Points:
- WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.
- “Kane has taken their revyve™ Antimicrobial Wound Gel and loaded it into this new, patent-pending delivery system creating a highly differentiated product ideal for burns and other sensitive wounds”, stated Dr. Gregory Schultz, Chief Scientific Officer of Kane Biotech.
- “The spray application makes it very easy to apply to the wound, and its thermo-reversible properties allow the gel to adhere to the skin on contact and makes it very easy to rinse off with cool water.
- “We believe this new application system with its optimum spray pattern, will have such a significant impact on treating sensitive wounds, in particular burns, that Kane has filed a patent”, said Marc Edwards, Chief Executive Officer of Kane Biotech.
Retrieved on:
Thursday, January 25, 2024
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.
Key Points:
- WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.
- The international conference will take place from January 27 to February 1, 2024 in Maui, Hawaii and covers the latest advancements in wound healing, burn care, and infection control.
- During this conference, Kane Biotech will present along with other important voices involved in the care of soft tissue injuries and related complications.
- “I’m excited to be presenting Kane’s revyve™ Antimicrobial Wound Gel to the wound care community at the Boswick conference and believe it will be very well-received, particularly by practitioners focused on burn care.
